-5.9%
MDB vs GSK
+63.2%
-69.1%
-70.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.7% | -0.2% | +2.9% | +2.7% |
| 7D | -11.4% | +1.7% | -13.0% | -11.4% |
| 30D | -13.8% | +7.0% | -20.9% | -14.2% |
| 3M | -15.5% | -2.7% | -12.8% | -15.3% |
| 6M | +17.9% | +1.4% | +16.5% | +17.6% |
| YTD | -25.5% | +5.3% | -30.8% | -26.6% |
| 1Y | -12.1% | +10.6% | -22.7% | -14.2% |
| 3Y | -5.9% | +62.6% | -68.5% | -18.1% |
| All | -5.9% | +63.2% | -69.1% | -18.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling